P2-323: Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey  by Yumuk, Perran F. et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S701
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
patients were still alive. For these patients, the survival was calculated 
until March 8, 2007. 
Results: Between October 2001 and December 2006, a total of 46 
NSCLC patients were treated. Two patients were not evaluable because 
we could not ﬁnd his data ﬁle. Characteristics of patients were as fol-
lows: Median age 56 years (range 41-72), male 41, female 3 and PS 0 
= 7 / 1 = 37. Histologic diagnosis was adenocarcinoma in 17 patients, 
squamous cell carcinoma in 5 and undifferentiated NSCLC in 22. 
Brain metastasis were present 7 patients (16%) prior starting the treat-
ment. Median number of cycles were 3.0 (range 1-6). In 45 evaluable 
patients, complete responses were seen in 1 patient ( 2.3%), partial 
response in 15 (34.1%) and disease stabilization in 19 ( 43.2%). In total 
of 140 cycles, grade 3-4 neutropenia, grade 3-4 leukopenia and grade 
3-4 anemia occured in 16.5%, 10% and 0.7% respectively. One fatal 
event was observed. The median survival was 285 days (95% CI [172-
397]) and at 1 and 2 years survival were 39% and 9.5%, respectively.
Conclusion: The combination of cisplatin plus vinorelbine is an active 
and tolerable regimen in Turkish patients with metastatic NSCLC.
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Background: Single-agent chemotherapy has been considered as 
standard treatment for elderly patients with non-small cell lung cancer 
(NSCLC). However recent subset analyses suggest that platinum-
based combination chemotherapy may be safely administered to the 
elderly with good performance status (PS). We evaluated the efﬁcacy 
and safety of carboplatin and docetaxel in a phase II study of elderly 
patients aged 70 years or older.
Methods: Chemotherapy-naive patients aged ≥70 years with advanced 
NSCLC (IIIB-IV), ECOG performance status (PS) of 0-2, a measurable 
lesion, and adequate organ functions were enrolled. Patients received 
carboplatin (AUC 5) and docetaxel (60 mg/m2) administered on day 
1 every 3 weeks. The primary endpoint was response rate (RR). This 
study, with a planned sample size of 25, had 80% power to support the 
hypothesis that the true RR was >30%, and 5% signiﬁcance to deny the 
hypothesis that the true RR was <10%. 
Results: Between October 2003 and April 2006, 30 elderly patients 
with NSCLC were enrolled in the study and all patients were treated. 
Demographics: M/F 20/10; PS 0/1/2 2/23/5; median age 75 (range 70-
84). Median number of treatment cycles was 3.5. Responses in the 30 
evaluable patients included 1CR; 13PR; for an objective RR of 46.7% 
(95%CI 28.8-64.6%). By January 4, 2007, 21 (70.0%) of 30 patients 
had died. Median follow-up for survival was 8.4 months. The median 
time to tumor progression was 4.4 months, and the median survival was 
9.9 months. The 1-year survival rate was 43.3%.Grade 3/4 hematologic 
toxicities included leukopenia (80.0%), neutropenia (86.7%), anemia 
(16.7%) and thrombocytopenia (3.3%). Non-hematologic toxicities 
were mild with no grade 4 toxicities; grade 3 nausea (10.0%), anorexia 
(30.0%), diarrhea (13.3%), fatigue (6.7%), allergic reaction (6.7%), 
pneumonitis (3.3%), febril neutropenia (16.7%) and infection (10.0%) 
were observed. 
Conclusion: The combination of carboplatin and docetaxel was safe 
and promising for the treatment of chemotherapy-naive elderly patients 
with advanced NSCLC. This regimen warrants further evaluation in a 
phase III trial.
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Background: Lung Cancer is one of the ﬁve most diagnosed cancers in 
Turkey. Treatment outcomes of 353 patients with advanced or metastat-
ic NSCLC who were treated in Marmara University Oncology Clinics 
between April 1997 and March 2007 were evaluated. 
Methods: All patients were diagnosed histologically or cytologically 
and staged with CAT scans. Patients with WHO performance status 
(PS) 2 and lower received chemotherapy (CT). A platinum analogue 
was used in combination with etoposide, vinorelbine, gemcitabine or 
taxanes as the ﬁrst line treatment in 83% patients. Elderly (65 years and 
older) or patients with poor PS (PS=2) were treated with single agent 
CT. Three to 6 cycles of treatment was administered depending on 
clinical or radiological response. Radiation therapy to primary tumor 
was administered to stage III patients after completion of ﬁrst line CT 
and to symptomatic stage IV patients for palliation. Eligible stage IIIA 
patients (16%) were operated. Second line treatment was offered to 
patients with progressive disease for 3 to 6 cycles. 
Results: Median age was 60 years (range: 29-87) and 80% of pa-
tients were male. Histological subtypes were squamous cell in 33%, 
adenocarcinoma in 35%, NSCLC in 30% and large cell cancer 2%. PS 
was 0 in 53% of the patients. Fifteen percent of the patients were stage 
IIIA, 22% were stage IIIB, and 63% were stage IV. The median number 
of cycles administered was 3. At a median follow-up was 11 months 
(range 1-82), 71% of patients died. Median overall survival (OS) was 
14 months, 1-year and 2-year OS ratios were 54% and 27%, respective-
ly. Median time to progression (TTP) was 5 months; 1-year progres-
sion free survival (PFS) ratio was 16%. Women, patients with stage III 
disease, and PS 0 or 1 lived signiﬁcantly longer (p=0.01, p=0.03, and 
p<0.001, respectively). Age, histology, smoking history or type of CT 
didn’t have any statistically signiﬁcant effect on survival in univari-
ate analysis. Only stage had an impact on OS in multivariate analysis. 
Stage was also the only factor on PFS (p<0.001). 
Conclusions: Advanced staged NSCLC patients has poor prognosis. 
Our results are consistent with the world literature.
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